Eli Lilly’s weight loss drugs have been driving strong sales, with the company positioned as a leader in the market. The success is attributed to drugs like tirzepatide, which have shown significant weight loss results. Additionally, Lilly’s latest weight loss candidate, retatrutide, demonstrated exceptional performance with an average weight loss of over 28% over 68 weeks. The drug’s three-pronged approach makes it stand out in the weight loss market, and the company plans to submit it for regulatory review soon. This success bodes well for Lilly’s future in the expanding weight loss drug market, estimated to reach $100 billion in the next decade.

Read more at Nasdaq: Eli Lilly Just Delivered Fantastic News to Investors